Such oligomerization for IgM is immunologically superior in activating the complement system than monomeric forms11, making IgM variants suitable candidates for targeting circulatory metastatic cancer cells that would be abated by immobilization of antigens via agglutination. Here, CD40LG is linked to cancer.